|
|
Article: Serono Completes Second Phase III Trial of its Proprietary Recombinant Human Growth Hormone for HIV-Associated Adipose Redistribution Syndrome (HARS).
- Article from:
- PR Newswire
- Article date:
- January 9, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Successful Completion of Trial Meets Pre-Specified Primary and Major Secondary Endpoints
GENEVA, Switzerland and ROCKLAND, Massachusetts, January 9 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO NYSE: SRA) announced today the completion of its pivotal Phase III double-blind, placebo-controlled trial of Serono's recombinant human growth hormone in the treatment of HIV-associated Adipose Redistribution Syndrome (HARS), which met all pre-specified primary and major secondary endpoints. Serono plans to submit the file to the FDA in the first half of 2006 and expects that the data will be presented at upcoming scientific meetings.
More than 300 patients ...